Discounted Cash Flow
Regeneron Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $4.9b | $895.5m | $961.5m | 18.4% | $8.55 |
| 2017 | $5.9b (20.8%) | $1.2b (33.8%) | $1.0b (7.6%) | 20.4% (10.8%) | $11.27 (31.8%) |
| 2018 | $6.7b (14.3%) | $2.4b (104.0%) | $1.8b (75.2%) | 36.4% (78.5%) | $22.65 (101.0%) |
| 2019 | $7.9b (17.2%) | $2.1b (-13.4%) | $2.0b (10.4%) | 26.9% (-26.1%) | $19.38 (-14.4%) |
| 2020 | $8.5b (8.1%) | $3.5b (66.0%) | $2.0b (0.2%) | 41.3% (53.7%) | $32.65 (68.5%) |
| 2021 | $16.1b (89.1%) | $8.1b (129.9%) | $6.5b (225.9%) | 50.2% (21.5%) | $76.40 (134.0%) |
| 2022 | $12.2b (-24.3%) | $4.3b (-46.3%) | $3.4b (-48.0%) | 35.6% (-29.1%) | $40.51 (-47.0%) |
| 2023 | $13.1b (7.8%) | $4.0b (-8.9%) | $3.7b (7.9%) | 30.1% (-15.4%) | $37.05 (-8.5%) |
| 2024 | $14.2b (8.3%) | $4.4b (11.6%) | $3.5b (-3.5%) | 31.1% (3.1%) | $40.90 (10.4%) |
| 2025 | $14.3b (1.0%) | $4.5b (2.1%) | $3.8b (6.4%) | 31.4% (1.1%) | $43.07 (5.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.